Famitinib

DB11741InvestigationalSmall molecule

Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and Vascular endothelial growth factor receptor 1
Curator reviewed
Formula / weight: C₂₃H₂₇FN₄O₂ · 410.493 g/mol (avg)
Code names: SHR-1020

Resolves to

Compound

UNII768FW21J3LCAS1044040-56-3ChEMBLCHEMBL1278146PubChem16662431

Structure

InChIKeyGKEYKDOLBLYGRB-LGMDPLHJSA-NSMILESCCN(CC)CCN1CCC2=C(C(C)=C(N2)\C=C2/C(=O)NC3=CC=C(F)C=C23)C1=O

Targets

P35968KDRP35916FLT4P17948FLT1P10721KITP36888FLT3P09619PDGFRBP16234PDGFRA

What you can answer from here — as of September 21, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

67Clinical trialsPhase, status and sponsor resolved per trial

23+ReferencesStructured and connected to the statements they support

Which drugs share a target with Famitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account